Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 31 of 88 · 4214 articles
This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...
Children with IBD and neurodevelopmental disorders may face different perioperative courses after colectomy — notably longer preoperative stays, greater need for nutritional support, and higher risk of postoperative...
This study suggests a new preclinical approach to help the gut lining heal in ulcerative colitis by targeting macrophage metabolism (myeloid AMPK) rather than directly treating epithelial cells. That could matter for...
This paper describes a novel nanozyme that reduced oxidative stress and inflammation in preclinical models of colitis and enteropathic arthritis — a possible future therapeutic approach that targets ROS in inflamed gut...
A national pediatric IBD registry from Colombia summarizes diagnosis age, disease types, treatment patterns (including rising biologic use), and outcomes—information that can inform families and clinicians about regional...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Immunity, inflammation...
Low muscle mass before ileocolic resection appears linked to higher short-term surgical complications and higher rates of endoscopic recurrence — information that could affect preoperative assessment and planning for...
This matters because it documents organising pneumonia occurring during biomarker-confirmed UC remission and emphasizes that lung disease in IBD patients may be disease-intrinsic rather than always drug-induced. Expert...
The ENS–gut microbiota field intersects with IBD research through shared mechanisms (neuroinflammation, neuro‑immune interactions) and potential microbiota‑based therapies, so mapping trends helps patients and clinicians...
The study describes a new berberine-containing nanocomplex that reduced inflammation and improved gut barrier function in cell, mouse, and organoid models of ulcerative colitis, suggesting a potential new direction for...
Patient-centered measures help clinics track and improve care experiences important to people with IBD. A validated patient-developed PREM could better reflect patient priorities and support quality improvement in UK IBD...
Wearable-derived digital biomarkers aim to detect flares earlier and reduce reliance on questionnaires; patients' acceptance is essential for real-world use. High reported willingness suggests patient-centered...
Trials testing intestinal ultrasound–guided treat-to-target strategies and late-stage therapies could change how Crohn’s disease is monitored and treated if they show improved outcomes.
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
Cure8 could only read part of this source from Frontline Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Infliximab.
Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...
If confirmed, differences between tirzepatide and GLP-1RAs could influence medication choice for people with IBD who need weight-loss or glucose-lowering therapy. Reduced IV steroid use suggests fewer severe flares...
Cure8 found this source from Intestinal research, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Azathioprine, and Immunomodulators. Open the original article for the full...
Microplastics are a widespread environmental exposure that this review links to biological changes relevant to IBD — intestinal barrier damage, microbiome shifts, and immune activation — so patients and clinicians may...
AIP-2 is a pancreas-specific autoimmune condition that commonly co-occurs with IBD, especially ulcerative colitis. Recognizing AIP-2 is important because it may present like acute pancreatitis or a pancreatic mass and...
Obituaries that mention Crohn’s disease can help the IBD community by acknowledging lived experience, caregiving burdens, and directing support to relevant charities. They also humanize long-term disease impact.
The study suggests there may be stage-specific differences in mucosal IgA and IgG plasma cell patterns in UC, which could help researchers understand mucosal immunity changes across active disease, quiescence, and...
The study suggests FMT can clear mucosal adherent‑invasive E. coli (AIEC) in some people with Crohn’s disease and alters mucosal microbiome features linked to inflammation, which could be relevant to microbiome‑targeted...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...
Knowing which treatment target (symptom control alone versus adding endoscopic and histological remission) leads to better long-term outcomes could change how aggressively clinicians treat ulcerative colitis and what...
This trial studies adalimumab safety and pediatric dosing in children with moderate–severe Crohn's disease, which is directly relevant to families and clinicians considering anti-TNF therapy for pediatric IBD.
Intestinal ultrasound can assess IBD inflammation without radiation but interpretation varies by operator. Developing AI tools to measure bowel wall thickness and other features could standardize and speed image...
If confirmed in clinical trials, targeting NAD+ metabolism or removing senescent immune cells could become new approaches to treat ulcerative colitis, especially for patients with severe disease or who do not respond to...
The intestinal barrier changes in inflammation and can alter how oral nanocarriers interact with mucus and epithelium; understanding this is important for designing delivery systems that achieve local therapeutic benefit...
Many people with IBD remain symptomatic even when tests show little or no inflammation; recognising these persistent symptoms as a separate treatment target could improve quality of life. This reframes care to address...
Work participation and sick leave affect daily life, income, and quality of life for people with IBD. Understanding when sick leave is more common can help patients, employers, and clinicians plan support around...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Computer Methods in...
People with IBD (ulcerative colitis or Crohn’s/regional enteritis) may develop vitamin K–related hypoprothrombinemia; this updated label describes when and how vitamin K (phytonadione) is used and emphasizes INR...
Dexamethasone is a systemic corticosteroid with an official label that still includes short‑term use to "tide the patient over a critical period" in Crohn's disease (regional enteritis) and ulcerative colitis.
Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.
ITB can closely mimic Crohn’s disease, so this study is relevant because it describes diagnostic test yields and illustrates that targeted TB testing and therapeutic trials of antituberculosis treatment can help...
The study raises the possibility that perinatal exposure to nanoplastics could have lasting, sex-specific effects on gut health and make adult offspring more susceptible to intestinal inflammation. This may be relevant...
The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.
This study shows that sodium butyrate, a metabolite produced by gut bacteria, changed brain imaging measures and reduced inflammation in mice with experimental IBD, supporting the idea that gut-derived compounds can...
Fatigue affects more than half of people with IBD and is a leading cause of impaired quality of life. A machine-learning approach that identifies distinct patient-level patterns may help researchers and clinicians...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Gastroenterology &...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from Gastroenterology & hepatology.
IL-22 links microbial metabolites to epithelial repair and inflammation; clarifying these pathways could inform future therapies or dietary/microbiome approaches to promote mucosal healing without worsening inflammation.
This review highlights a new, non-live microbiome-based therapy approach (probiotic-derived EVs) that could in future modulate gut immunity and barrier function without using live microbes. For people with IBD, such...
Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
Patients with hidradenitis suppurativa have higher baseline IBD risk, and IL-17 inhibitors are effective HS treatments. People with Crohn’s disease or ulcerative colitis (or those at risk) may worry whether these drugs...
